Étiquette : EHA
-
Advanced BioDesign Presents ODYSSEY Clinical Data and New Preclinical Findings Supporting Combination Strategies at EHA 2026
Lyon, France – 2nd of June 2026 — Advanced BioDesign, a biotechnology company developing first‑in‑class ALDH1 inhibitors for treatment‑resistant cancers, today announced the presentation of new data at the 2026 European Hematology Association (EHA) Congress. The company highlights: clinical results from the Phase 1 ODYSSEY study evaluating ABD-3001, a first-in-class ALDH1 inhibitor, in patients with…
